arrow
S

Susan E. Prockop

University of California Los Angeles Medical Center
H指数:43
被引数:6,603

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International clinical consensus on leukocyte adhesion deficiency-I: Modified Delphi analysis

白细胞黏附缺陷I型的国际临床共识:改良德尔菲分析

2026-05-011
OAAI
Expression of HLA-B*35 is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-based Hematopoietic Cell Transplantation

HLA-B*35的表达与PTCy-based造血细胞移植后巨细胞病毒(CMV)病毒血症及临床显著CMV感染风险的增加相关。

2025-09-210
PRE
Treating and triggering hyperinflammation: tackling hemophagocytic lymphohistiocytosis and HLH-like syndromes in the pediatric cell therapy and critical care setting

治疗和诱导高炎症反应:在儿科细胞疗法和重症监护环境中应对噬血细胞性淋巴组织细胞增多症及HLH样综合征

2025-09-200
OAAI
Harmonized Immune Recovery Monitoring after HCT: Evidence & Practical Guidance from the Westhafen Intercontinental Group

异基因造血干细胞移植后免疫重建监测的标准化:Westhafen Intercontinental Group的证据与实践指南

2025-09-050
OAAI
CAR T cell therapy for children with rheumatic disease: the time is now

儿童风湿性疾病的cart细胞治疗: 现在是时候了

2025-07-020
PRE
A single dose of a CD137 antibody–drug conjugate protects rhesus macaque allogeneic HCT recipients against acute GVHD

单剂量CD137抗体-药物偶联物可保护恒河猴同种异基因HCT受体免受急性移植物抗宿主病的影响

Blood
IF23.1
2025-06-140
PRE
Delayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults

造血细胞移植后T细胞恢复延迟与成人总生存率降低相关

2025-04-210
OA
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

同种异体现货型CAR T细胞疗法用于复发或难治性B细胞恶性肿瘤

2025-02-051
OA
The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity

高尔基复合体调控自然杀伤细胞溶酶体定位,以促进细胞毒性的方向性

2025-01-010
OAAI
Multiomics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature

多组学分析揭示人类RAG缺陷症表现出独特的免疫失调模式,但具有共同的炎症特征

2025-01-010
OA
The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell committee

预处理方案在自体和离体转基因造血干细胞治疗中的作用: 来自ISCT干细胞委员会的建议

2025-01-010
OAAI
Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

HLA-B*35的表达与接受Ptcy为基础造血细胞移植的患者发生巨细胞病毒(CMV)病毒血症和临床显著CMV感染风险增加相关。

BLOOD
IF23.1
2024-11-050
PRE
Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

早期巨细胞病毒(CMV)病毒载量负担可预测接受Ptcy为基础的造血细胞移植患者晚期临床显著CMV感染。

BLOOD
IF23.1
2024-11-050
PRE
International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell–based genomic therapies and the challenges faced

国际细胞与基因治疗学会干细胞工程委员会关于基于造血干细胞和祖细胞的基因组疗法的现状和面临的挑战的报告

2024-11-015
PRE
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity
2024-09-271
OAAI
Strategic infection prevention after genetically modi fi ed hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee

基因修饰造血干细胞治疗后的战略性感染预防: 国际细胞与基因治疗学会干细胞工程委员会的建议

2024-07-011
OAAI